Fellowship ​

The Australian Academy of Health and Medical Sciences elects the best and brightest minds in the field of medical and health sciences as Fellows.

Fellows are elected in recognition of their outstanding achievements and exceptional contributions to the sector. The Fellowship are acknowledged for their clinical, non-clinical, leadership, industry and research contributions.

Find Fellows of the AAHMS

To find Fellows of our Academy either use the search form below or download the full list of current Fellows here.






NHMRC Senior Principal Research Fellow & Laboratory Head, Molecular Medicine Division
Walter and Eliza Hall Institute of Medical Research

Professor Len Harrison was among the first to characterise the insulin receptor, including its clinical relevance. He inaugurated Australian research into the pathogenesis, pre-clinical diagnosis and prevention of type 1 diabetes (T1D). He discoveries include: mechanisms of pancreatic beta-cell destruction, the primacy of insulin as an autoantigen, protective immune tolerance induced by insulin, T-cell epitopes in pancreatic beta-cell autoantigens; insulin resistance as a risk factor for T1D and the CD52-Siglec system of immune regulation. Following ‘proof-of-concept’ studies in mice, he has conducted a series of trials, currently Phase 2b, of a nasal insulin vaccine to prevent T1D.

NHMRC Senior Principal Research Fellow & Professor of Neuroscience
UNSW Medicine & Neuroscience Research Australia

Professor Glenda Halliday’s research on Parkinson’s disease (PD) and dementia with Lewy bodies is incorporated into diagnostic research criteria-only Australian on current task force redefining PD diagnosis. In frontotemporal dementia, performed the 1st large-scale clinicopathological and survival analyses, developed a disease severity staging scheme-research also incorporated into diagnostic criteria and international studies identifying novel genes and pathologies. 2006-7 president of Australian Neuroscience Society (ANS), secretary of Asia/Pacific Regional Committee of International Brain Research Organisation (2010-), and on scientific advisory boards for an international and australian research institution. 2011 ANS Nina Kondelos Prize winner for outstanding neuroscience, and NHMRC high achiever.

Emeritus Professor, National Centre for Youth Substance Use Research
The University of Queensland

Professor Wayne Hall is internationally-recognised in the fields of addiction and mental health. He has made significant and sustained contributions advancing understanding of the epidemiology of alcohol and drug use, mental disorders, and harms related to alcohol and drug use. He has made major contributions to the formulation of Australian national drug and alcohol policy as a researcher and advisor to Federal and state governments. He has demonstrated continuous and conspicuous service advancing the profession as an expert advisor to WHO, and as an elected Member of the International Narcotics Control Board of the UN Economic and Social Council.

Deputy Director and Head, Macular Research Unit
Centre for Eye Research Australia

Professor Guymer is Australia’s only academic ophthalmologist to focus exclusively on age-related macular degeneration (AMD), the most common cause of poor vision in our society. She established new AMD treatment clinics at the Royal Victorian Eye and Ear Hospital (the first Australian public hospital to do so); delivered state-of-the-art imaging and functional techniques; and contributed to a commercial genetic test to assess a person’s risk of AMD. Prof Guymer leads the world’s-first nanosecond laser intervention trial, which will revolutionise prophylactic treatment for AMD if successful. She has achieved distinction, frequently providing expert opinion to government, media and support groups.

Emeritus Fellow
QIMR Berghofer Medical Research Institute

Professor Green has provided an unparalleled body of evidence regarding the causes and preventability of cancers of the skin, the latter forming the basis of clinical and public health prevention strategies in the USA, Europe, Australia and of WHO recommendations. For two and half decades she has served on numerous health and medical science boards and committees, both national and international, either as member or chair and since 2008 she has served on the International Commission for Non-Ionising Radiation Protection. She was Deputy Director of QIMR for 12 years till 2012. Professor Green’s contributions have been recognised in a range of professional and community awards.

Executive Director
Victor Chang Cardiac Research Institute

Professor Robert M. Graham is internationally regarded for his contributions to our understanding of cardiovascular homeostatic and disease mechanisms via adrenergic receptors and coupled signal transduction pathways; studies that have utilised the tools of molecular and cell biology, biochemistry and biophysics. Nationally he is recognised for establishing a leading cardiovascular research institute, which also provides comprehensive research training and aims to rapidly translate research advances into improved clinical care. As well as directing the Institute, he remains actively engaged in clinical medicine, in undergraduate and postgraduate teaching, in community engagement and in providing leadership in academic health and medical science.

Principal Research Leader and Laboratory Head
Institute for Glycomics, Griffith University

Professor Michael Good AO is an international leader in vaccine research and development. For over 25 years he has studied immunity to the malaria parasite and to Streptococcus pyogenes with the goal of identifying novel vaccine strategies. These organisms are responsible for the loss of over 1.5 million lives each year. He is currently undertaking Phase I vaccine trials for both. He is employed at Griffith University where he holds an NHMRC Australia Fellowship. His Awards include the Eureka Prize for Leadership and a Queensland Great Award. He was elected to Honorary Fellowship of the Royal Australasian College of Physicians, The Queensland Academy of Arts and Sciences and the Australian Academy of Technological Sciences and Engineering. He is a former Director of QIMR and a former Chairman of NHMRC Council.

Director, Centre for Research in Evidence-Based Practice
Bond University

Paul Glasziou FRACGP, PhD is Professor of Evidence-Based Medicine at Bond University and a part-time General Practitioner. He was the Director of the Centre for Evidence-Based Medicine in Oxford from 2003-2010. His key interests include identifying and removing the barriers to using high quality research in everyday clinical practice, reducing waste in research, and preventing overdiagnosis. He is the author of seven books related to evidence based practice: Systematic Reviews in Health Care, Decision Making in Health Care and Medicine: integrating evidence and values, An Evidence-Based Medicine Workbook, Clinical Thinking: Evidence, Communication and Decision-making, Evidence-Based Medicine: How to Practice and Teach EBM, and Evidence-Based Medical Monitoring: Principles and Practice, and Testing Treatments. He has authored over 250 peer-reviewed journal articles. He is the recipient of an NHRMC Australia Fellowship which he commenced at Bond University in July, 2010.



Emeritus Professor
QIMR Berghofer Medical Research Institute

Professor Frank Gannon is an international thought leader and researcher. His contributions have been recognised by election to EMBO, Acadamiae Europaeae, Royal Irish Academy, European Academy of Cancer Sciences, Mexican Academy of Medicine and Honorary doctorates from three universities. He leads a major medical research Institute active in discovery and translational research. His research has ranged from the isolation of one of the first eukaryote genes to the provision of new insights on the control of gene expression, based on studies of the estrogen receptor. He has also contributed over 100 editorials on topics of relevance to science and society.

Chair, Foundation Board
Translational Research Institute, University of Queensland

Professor Ian Frazer works to raise awareness and funds for medical research through his role with The University of Queensland (UQ) and as Chair of the TRI Foundation Board.  He is also the current Chair of the advisory board advising the commonwealth government on the use of the Medical Research Future Fund, a member of the Commonwealth Science Council and President of the Australian Academy of Health and Medical Science.

At UQ, Professor Frazer works with the Deputy Vice-Chancellor (Research) as an advisor on medical research and with the Vice-Chancellor on fundraising through the University’s Campaign Committee.  He also leads a research program at TRI on skin cancer immunology with staff from UQ’s Diamantina Institute and continues to work with Admedus Vaccines on a herpes vaccine and new vaccine technologies.

As the founding Chief Executive Officer and Director of Research for the Translational Research Institute (TRI) in Brisbane, Australia, Professor Frazer lead the development of a world-leading biomedical research facility focused on translating scientific knowledge into practical benefits for the community.  Combing the intellect of its partners: the University of Queensland’s Diamantina Institute, Mater Research and School of Medicine; Queensland University of Technology Institute of Health and Biomedical Innovation; and the Princess Alexandra Hospital Centres for Research, with a Clinical Research Facility and a co-located biopharmaceutical manufacturer, TRI has the capacity to discover, produce, test and manufacture new treatments and vaccines in one location.

Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with the University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence as CEO and Director of Research for TRI. In February 2015, he relinquished this role to focus more on his research.

Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister’s Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and was recently elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours. In 2014, Professor Frazer was elected as the inaugural President of the Australian Academy of Health and Medical Sciences.


About Fellowship with AAHMS

Our Fellows sit at the heart of everything we do. They represent Australia’s leading minds in health and medical sciences, having been recognised for their clinical, non-clinical, leadership, industry and research contributions.

To be considered for election to the Academy’s Fellowship, a candidate must show exceptional professional achievement in a field related to health and/or medicine.

Fellows contribute to the projects and activities of the Academy and must be willing to be active participants.

Successful Fellowship candidates will have shown:

  • Outstanding leadership in their field.
  • Significant and ongoing involvement with issues of health care, prevention of disease, education, research, and health services policy and delivery.

Candidates for Fellowship should meet the following criteria:

  • National and International recognition for excellence in health and medical science
  • Significant, sustained and ongoing contributions to advance health and medical science in Australia (relative to opportunity)
  • Contribution to the profession through leadership and mentorship
  • Raised public understanding and promoting health and medical science in the broader community

Download criteria for Fellowship

Each year, current Fellows of the Academy are invited to nominate up to four new candidates who meet the criteria and fulfil the required expectations.

To ensure the Academy has a representative and diverse membership, Fellows nominating two new candidates are asked to include only a maximum of one man, and Fellows nominating four new candidates are asked to include only a maximum of two men.

How to make a nomination

Fellows wishing to nominate a candidate for Fellowship should contact the secretariat to confirm candidate eligibility and receive and instructions on how to submit the completed nomination documentation online. 

Fellows wishing to nominate a candidate for a Corresponding Fellowship should contact the secretariat for more information.

Secretariat contact details
Email: [email protected]

Phone: 07 3102 7220

Nomination guidelines for ordinary Fellowship

October 2023
Newly elected Fellows of 2023 are inducted at the Annual Meeting.

18 September 2023- 30 November 2023
Nominations are invited from existing Fellows until the closing date of 30 November.

December 2023
Nominations allocated to Selection Committees.

January – April 2024
Referees’ reports sought.

Early May 2024
Selection Committees meet to consider nominations and provide final recommendations to the Council.

Early-to-mid-July 2024
Council meets to finalise recommendations.

Late July 2024
Full Fellowship invited to comment on recommended new fellows.

August 2024
Election results are shared with proposers and candidates (under embargo).

October 2024
Newly elected Fellows of 2024 inducted at the Annual Meeting.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.